AzTrials
AzTrials

Handgrip StrengthNCT07289698

Handgrip Strength Increases the Pressure in the Portal and Left Gastric Veins in Cirrhotic Patients

An observational study of Handgrip Strength and Transjugular Intrahepatic Portosystemic Shunts (TIPS), run by Shanxi Provincial People's Hospital at 2 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Handgrip strength
Type of treatment
Medical device
How many people
64 participants
Where
2 sitesChina
Study dates
31 Dec 2025to 2 Apr 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: This observational study was performed in two centers in China (The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology [Luoyang], and Shanxi Provincial People's Hospital [Taiyuan]) . They serve as the major tertiary referral center for the management of liver cirrhosis and its complications in our country.

Who may be able to join

  • adult patients (≥18 years of age) with cirrhosis and a history of variceal bleeding, who were preparing for TIPS creation for secondary prophylaxis against variceal bleeding

Who cannot join

  • Severe congestive heart failure, or severe untreated valvular heart disease
  • Moderate to severe pulmonary hypertension
  • Uncontrolled systemic infection
  • Lesions (e.g., cysts) or tumors in the liver parenchyma that preclude TIPS creation
  • Overt hepatic encephalopathy
  • Unrelieved biliary obstruction
Show all 11Show fewer
  • Child-Pugh score > 13
  • Model for end-stage liver disease (MELD) score > 18
  • International normalized ratio (INR) > 5
  • Platelet count < 20×109/mm3
  • Participants who had undergone hand or wrist surgery within the previous 3 months or were unable to hold the dynamometer with the testing hand were excluded from the study.

Trial locations and contacts

2 sites in 1 country.

China2 sites
  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, 471003

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, 030012

Other trials in China

About this study

1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Objective The purpose of the study is to examine the effects of Handgrip strength on portal vein and left gastric vein pressure, blood flow velocity and direction in patients with liver cirrhosis.

  1. Method: observational study. Detection Timing: Doppler ultrasound was employed to determine the portal flow velocity and direction at baseline and during the handgrip strength test in cirrhotic patients with a history of variceal bleeding. Three days later, prior to TIPS placement, the pressures in the portal pressure and gastric vein pressure were measured both before and after handgrip strength. Furthermore, carvedilol and vasoactive drugs were discontinued three days before the study commenced. 4. Elaboration of the Research Hypothesis 4.1. Core Hypothesis The handgrip strength level in patients with liver cirrhosis is correlated with portal venous system hemodynamic indices. Specifically, enhanced handgrip strength may affect portal hypertension and the hemodynamics of varicose veins by improving systemic muscle function or circulatory status. 4.2. Speculation on potential mechanisms Association between muscle function and circulation: As a representative of systemic muscle function, increased handgrip strength may reflect an increase in cardiac output or changes in splanchnic vascular resistance, thereby influencing portal venous hemodynamics.
Being tested
Handgrip strength

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Handgrip strengthDevice

    Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests

Study groups in NCT07289698
Study groupRoleWhat they receive
Portal pressure measurement groupNot described
Receives: Device: Handgrip strength
Doppler Ultrasound Measurement GroupNot described
Receives: Device: Handgrip strength

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. portal pressure

    Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.

    Measured: through study completion, an average of 5 minutes

  2. left gastric vein pressure

    Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.

    Measured: through study completion, an average of 5 minutes

  3. portal flow velocity

    Measured: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength

  4. Portal vein blood flow direction

    Measured: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength

Secondary outcomes (25)
  1. Serum albumin (g / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  2. alanine aminotransferase(IU / L)

    Pre-TIPS baseline characteristics, date (n=32)

    Measured: Baseline

  3. aspartate aminotransferase (IU / L)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  4. Total bilirubin (µmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  5. Prothrombin time (second)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  6. Fasting blood glucose (mmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  7. triglyceride (mmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  8. Total cholesterol (mmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  9. Serum creatinine (µmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  10. Serum potassium (mmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  11. Serum sodium (mmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  12. Serum chloride (mmol / l)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  13. Platelet count (× 109 / mm3)

    Pre-TIPS baseline characteristics ,date (n=32)

    Measured: Baseline

  14. height

    Measured: Baseline

  15. weight

    Measured: Baseline

  16. Model for end-stage liver disease score

    Model for end-stage liver disease score: 6-40, the higher scores mean a worse outcome.

    Measured: Baseline

  17. Child-Pugh score

    Child-Pugh score: 5-15, the higher scores mean a worse outcome

    Measured: Baseline

  18. Esophageal varices before endoscopic treatment

    The diagnosis of esophageal varices and variceal bleeding in patients is confirmed by upper gastrointestinal endoscopy.

    Measured: Baseline

  19. Collateral vessels before TIPS placement

    Vascular angiography was performed prior to TIPS placement to diagnose collateral circulation. date (n=32)

    Measured: Baseline

  20. Ascites

    Prior to TIPS, ascites was evaluated by ultrasound in 32 patients with liver cirrhosis.

    Measured: Baseline

  21. Prior overt hepatic encephalopathy

    Measured: Baseline

  22. Etiology of cirrhosis

    Measured: Baseline

  23. Age

    Measured: Baseline

  24. Sex

    Measured: Baseline

  25. Handgrip Strength

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2025
  2. Study start31 Dec 2025
  3. Primary completion2 Apr 2026
  4. Study completion2 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
64 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07289698
Sponsor's protocol ID
MZ
Status last verified
Nov 2025
First submitted
4 Dec 2025
Last updated
6 Apr 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The way of sharing IPD: Sharing and email consultation will begin after December 31, 2027. Data collection and Management: Case record forms and electronic data captures.

Questions about this trial

What is this clinical trial studying?

An observational study of Handgrip Strength and Transjugular Intrahepatic Portosystemic Shunts (TIPS), run by Shanxi Provincial People's Hospital at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

portal pressure (time frame: through study completion, an average of 5 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in